Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total value of $39,460.60. Following the completion of the transaction, the insider now owns 59,883 shares of the company's stock, valued at approximately $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.76, for a total value of $8,254.40.

Travere Therapeutics Price Performance

Shares of TVTX traded down $0.15 during midday trading on Monday, reaching $18.71. The stock had a trading volume of 1,356,877 shares, compared to its average volume of 1,230,192. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -4.11 and a beta of 0.70. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.33. The company's 50-day moving average is $18.14 and its 200 day moving average is $13.90.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to analysts' expectations of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business's quarterly revenue was up 69.6% on a year-over-year basis. During the same period last year, the business earned ($1.17) earnings per share. On average, equities analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Travere Therapeutics from $20.00 to $23.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. Wedbush upped their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an "outperform" rating in a report on Wednesday, October 9th. Scotiabank raised their price target on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a "sector outperform" rating in a report on Friday, November 1st. Guggenheim boosted their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. Finally, Leerink Partners reiterated an "outperform" rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $23.67.

Institutional Trading of Travere Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning grew its stake in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company's stock valued at $335,000 after buying an additional 995 shares during the last quarter. Forefront Analytics LLC grew its position in Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company's stock worth $109,000 after acquiring an additional 1,237 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in Travere Therapeutics by 3.8% in the 2nd quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company's stock worth $626,000 after purchasing an additional 2,774 shares during the period. CWM LLC increased its stake in Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after purchasing an additional 3,065 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Travere Therapeutics by 20.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock valued at $279,000 after purchasing an additional 3,458 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.